Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 3/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7962507 | 0.84 | NPY5R (0.60) | NPY5RKCNH2ADRA1AALKBH3EGLN1 | |
| SCHEMBL7969172 | 0.82 | NPC1 (0.53) | NPY5RKCNH2ADRA1AALKBH3EGLN1 | |
| SCHEMBL2421049 | 0.81 | NPY5R (0.63) | NPY5RKCNH2ADRA1ANPBWR1DGAT1 | |
| SCHEMBL10140665 | 0.80 | MEN1 (0.45) | NPY5RKCNH2ADRA1AALKBH3 | |
| SCHEMBL7962503 | 0.79 | NPY5R (0.52) | NPY5RKCNH2ADRA1A | |
| SCHEMBL7970001 | 0.79 | GFER (0.56) | NPY5RADRA1AEGLN1 | |
| SCHEMBL7973969 | 0.78 | CHEK2 (0.57) | NPY5R | |
| SCHEMBL7976233 | 0.77 | PRSS1 (0.52) | NPY5R | |
| SCHEMBL7973178 | 0.76 | NPY5R (0.56) | NPY5R | |
| SCHEMBL3791087 | 0.75 | NPC1 (0.47) | NPY5RKCNH2ADRA1AALKBH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805939-A1 | Heterocyclic compounds as factor IXA inhibitors. | Merck Sharp & Dohme Corp. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| WO-2009143039-A2 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | NPY5R 652/4885KCNH2 2017/4885ADRA1A 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.